COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria -
COMMUNIQUÉ DE PRESSE
TUI Group: 10th consecutive quarter of Und. EBIT growth – Hotels, Cruises and TUI Musement driving improvement in FY25 Q1
TUI Group reports 10th consecutive quarter of underlying EBIT growth in FY25 Q1, driven by Hotels, Cruises, and TUI Musement. Q1 revenue up +13% to €4.9bn. Market + Airline segment shows 31% lower underlying EBIT due to investments for summer season -
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study
Onco-Innovations Limited introduces exclusive PNKP inhibitors to enhance sensitivity of cancer cells to radiation, potentially revolutionizing targeted cancer treatments
